26-06-2026. Casablanca, Morocco. Mediterrania Capital Partners (“MCP”), a leading private equity firm focused on growth investments across Africa, today announces the successful completion by Laprophan Group, one of its portfolio companies, of the acquisition of a controlling stake in Rivopharm, a Switzerland-based pharmaceutical company specialised in specialty medicines, dossier development, complex formulations and value-added pharmaceutical solutions.
The transaction represents a major milestone in Laprophan’s growth trajectory and reinforces the company’s ambition to build a diversified international pharmaceutical platform spanning Europe, Africa, the Middle East and selected global markets.
Founded more than 75 years ago, Laprophan is one of Morocco’s leading pharmaceutical groups and a longstanding pioneer in the country’s healthcare sector. Since MCP’s investment, the company has pursued an ambitious growth strategy focused on expanding its product portfolio, strengthening its industrial capabilities, enhancing operational excellence and accelerating international expansion.
The acquisition of Rivopharm marks Laprophan’s first acquisition in Europe and significantly strengthens the Group’s international footprint. Through Rivopharm’s Swiss manufacturing and development platform, as well as its subsidiaries in the United Kingdom, Germany and Lithuania, Laprophan gains direct access to key European markets and highly complementary pharmaceutical capabilities.
The combination creates a unique platform bringing together strong industrial assets, differentiated pharmaceutical development expertise, regulatory know-how and extensive commercialisation capabilities. The transaction also accelerates Laprophan’s expansion in the attractive B2B pharmaceutical segment and enhances its ability to serve partners and patients across multiple geographies.
Hatim Ben Ahmed, Managing Partner at Mediterrania Capital Partners, said: “This acquisition is a defining step in that journey. Rivopharm brings highly complementary capabilities, a strong European platform and significant opportunities for value creation. Together, Laprophan and Rivopharm are exceptionally well positioned to build a diversified international pharmaceutical group with a meaningful presence across Europe, Africa and the Middle East. We are proud to support Laprophan’s management team as they continue to execute on their long-term growth strategy.”
The transaction underscores Mediterrania Capital Partners’ commitment to supporting ambitious African companies in their international expansion and in building regional and global leaders across strategic sectors.